Tenaya Therapeutics, Inc. TNYA
0.35 USD 0.00 (+0.49%)
Regular-session close
0.36 +0.01 +3.81%
After hours · Nov 13, 7:48 PM ET
0.334 Day range 0.3582
0.30 52-week range 1.46
- YTD
- -50.96%
- 1 year
- -74.51%
News
benzinga.com Tenaya Therapeutics Q3 EPS $(0.08) Beats $(0.10) Estimate, Sales $1.697M Beat $800.000K Estimate Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.10) by 20 percent. This is a 33.33 percent increase over losses of…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers MaxCyte (NASDAQ:MXCT) shares rose 34.5% to $1.3 during Wednesday's regular session. The company's market cap stands at $102.6 million. Liquidia (NASDAQ:LQDA) stock moved upwards by 26.29% to…benzinga.com FDA Grants Regenerative Medicine Advanced Therapy Designation To Tenaya Therapeutics’ TN-401, Gene Therapy Candidate For Treatment Of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy RMAT Designation Supported by Positive Interim Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 which Demonstrated Reduced Arrhythmia Burden Additional Data and Updates on Regulatory…
benzinga.com Tenaya Therapeutics Q2 EPS $(0.20) Misses $(0.05) Estimate, Sales $1.110M Miss $10.000M Estimate Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.05) by 300 percent. This is a 42.86 percent decrease over losses of…
benzinga.com Tenaya Therapeutics Appoints Eric Hyllengren CFO, Effective July 13 Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of…
benzinga.com Tenaya Therapeutics Reports New Interim Safety And Efficacy Data From MyPEAK-1 Phase 1b/2 Clinical Trial Of TN-201 All Evaluable Patients Achieved Improvements in Multiple Hallmarks of MYBPC3-Associated HCMBenefits Among Cohort 1 Patients Sustained as Far Out as Two Years; Cohort 2 Patients Showed Greater Symptom…
benzinga.com Tenaya Therapeutics To Report New Interim Data From Cohort 1 And 2 Of Ongoing MyPEAK-1 Phase 1b/2 Trial Of TN-201 Gene Therapy For Adults With MYBPC3-Associated Hypertrophic Cardiomyopathy On June 3 Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of…
benzinga.com Tenaya Therapeutics' Gene Therapy Data Highlights Early Heart Rhythm Improvements Tenaya reported early RIDGE-1 data showing reduced arrhythmias and favorable safety for TN-401 in PKP2-related ARVC patients.
benzinga.com Earnings Scheduled For May 6, 2026 benzinga.com Tenaya Therapeutics Q1 EPS $(0.09) Misses $(0.06) Estimate, Sales $25.000M Beat $10.000M Estimate Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.06) by 50 percent. This is a 62.5 percent increase over losses of…
benzinga.com Tenaya Therapeutics Announces Acceptance Of Multiple Abstracts For Presentation At ASGCT Annual Meeting; To Feature New Clinical Data From Both Dose Cohorts Of RIDGE-1 Phase 1b/2 Trial Of TN-401 As Late-Breaking Oral Presentation Readout to Include One-Year Cohort 1 Results and Early Cohort 2 Data; Webcast Conference Call Planned to Review RIDGE-1 Data at ASGCTAdditional Presentations at ASGCT Showcase Tenaya's Work with…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session benzinga.com Tenaya Therapeutics Q4 EPS $(0.12) Beats $(0.13) Estimate Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.13) by 9.09 percent. This is a 57.14 percent increase over losses of…
benzinga.com Tenaya Therapeutics Presents Prelinical Data Of TN-301 At Muscular Dystrophy Association's Clinical & Scientific Conference 2026 Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of…
benzinga.com Tenaya Therapeutics Stock Jumps After New Alnylam Deal Tenaya Therapeutics stock jumps after announcing a research collaboration with Alnylam worth up to $1.13 billion in milestone payments.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session benzinga.com Tenaya Therapeutics Collaborates With Alnylam Pharmaceuticals To Discover Human Genetic Targets For Potential Development Of Disease-modifying Treatments For Cardiovascular Diseases Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of…
benzinga.com Tenaya Therapeutics Issues Update On Clinical Development Programs And Outlines Strategic Priorities For 2026; Aims To Build On Positive 2025 Interim TN-201 Results In H1 2026 Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK™-1 Trial of Adults with MYBPC3-Associated HCMExpects to…
benzinga.com Tenaya Stock Plunges After $60 Million Equity Offering Heart disease-focused Tenaya Therapeutics falls on high volume after pricing a $60 million offering and releasing new TN-401 data, while the FDA clears the TN-201 trial hold.
benzinga.com S&P 500 Down 1%; Broadcom Earnings Top Views
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session benzinga.com HC Wainwright & Co. Maintains Buy on Tenaya Therapeutics, Lowers Price Target to $3 HC Wainwright & Co. analyst Joseph Pantginis maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and lowers the price target from $5 to $3.
benzinga.com Dow Rises Over 100 Points; Lululemon Posts Upbeat Q3 Earnings benzinga.com Chardan Capital Maintains Buy on Tenaya Therapeutics, Lowers Price Target to $8 Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and lowers the price target from $9 to $8.
benzinga.com Tenaya Therapeutics Receives FDA Clearance To Resume MyPEAK‑1 Trial Of TN‑201 For MYBPC3‑Associated Hypertrophic Cardiomyopathy Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session benzinga.com Tenaya Therapeutics Reports Interim RIDGE‑1 Trial Data For TN‑401 Gene Therapy In PKP2‑Mutated ARVC TN-401 was Well Tolerated at 3E13 vg/kg dose Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week 8Clinically Meaningful Reductions in Arrhythmia Burden…
benzinga.com Chardan Capital Maintains Buy on Tenaya Therapeutics, Maintains $9 Price Target Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $9 price target.
benzinga.com Tenaya Therapeutics Q3 EPS $(0.12) Beats $(0.15) Estimate Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 22.58 percent. This is a 60 percent increase over losses of…
benzinga.com Reported Saturday, Tenaya Therapeutics Reports TN-201 Well Tolerated At 3E13 And 6E13 vg/kg With Managed Immunogenicity And No Dose-Limiting Toxicities In MyPEAK-1 MyPEAK-1 Data Presented During Late-Breaking Session at AHA Scientific Sessions 2025 with Simultaneous Publication in Cardiovascular ResearchTN-201 Has Been Generally Well Tolerated at Both…
benzinga.com FDA Places Clinical Hold On Tenaya Therapeutics' TN-201 Trial, Requests Protocol Amendment For Patient Monitoring And Immunosuppression Management The U.S. Food and Drug Administration ("FDA") has placed a clinical hold on MyPEAKTM-1,Tenaya Therapeutics, Inc.'s ("Tenaya") Phase 1b/2a clinical trial evaluating TN-201 in MYBPC3-associated…
benzinga.com Tenaya Therapeutics To Give Two Late-breaking Oral Presentations At The American Heart Association 2025 Scientific Sessions Taking Place November 7-10, 2025 Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of…
benzinga.com Top 4 Biotech Stocks Set For A Breakout: Momentum Scores Surge Several biotech stocks are showing renewed strength over the past week, with their Momentum scores soaring in Benzinga's Edge Stock Rankings.
benzinga.com US Futures Tumble As Traders Await Trump's Congress Address: 'Volatility Is Certainly Being Fed By Trump 2.0 Moves,' Says Expert U.S. stock futures declined on Tuesday following the worst trading day of 2025 on Monday. Futures fell in premarket trading except Nasdaq 100.benzinga.com Why Fluor Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Shares of Fluor Corporation (NYSE: FLR) fell during Tuesday’s session following fourth-quarter results.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Why Tredegar Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session Gainers Trevena, Inc. (NASDAQ: TRVN) shares surged 170% to $1.74 after the company announced the approval of OLINVYK in China.
benzinga.com Why SAP Shares Are Trading Higher By Around 6%? Here Are Other Stocks Moving In Friday's Mid-Day Session Gainers Mangoceuticals, Inc. (NASDAQ: MGRX) shares jumped 207% to $2.84. The company announced Thursday, that it's featured on Webull Corporate Communications Service Platform.
benzinga.com Why Nevro Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers Aditxt, Inc. (NASDAQ: ADTX) shares gained 68.6% to $1.45. Aditxt signed asset purchase agreement to acquire 50% ownership of Global Response Aid with rights to manufacture and market…
benzinga.com Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 56.6% to settle at $19.10 on Friday.
benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 283 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Friday Friday's session saw 236 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's session, 101 companies made new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 838 companies hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's trading, 528 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's session, 402 companies made new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 1076 companies hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 429 stocks made new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's session, 265 companies made new 52-week lows.
